

Biographical Outline

I graduated “*Summa Cum Laude*” from the Medical School of the National and Kapodistrian University of Athens, Greece. I completed my Internal Medicine training at the Athens University Laikon Hospital and the New York-Presbyterian Hospital, Weill Cornell Medical Center of Cornell University. I am a founding member of the International Osteoarticular Mycoses Study Consortium. I was trained in Infectious Diseases (ID) at the Athens University Laikon Hospital. I completed my PhD thesis on candidemia among patients with hematological malignancies at the Athens University Medical School and my Master in Public Health, at the School of Public Health, Athens Greece. I served for two months as a clinical observer at the HIV department of the Chelsea and Westminster Hospital, London under a scholarship of the Hellenic Society of Infectious Diseases, and for one year as Senior Clinical Fellow at the National Aspergillosis Centre, University Hospital of South Manchester. Then, I served for 14 months, as a Clinical Research Fellow in Infectious Diseases, at the St James’s University Hospital, The Leeds Teaching Hospitals, NHS Trust. For two years, I was Scientific Associate at the National and Kapodistrian University of Athens, and Attending Physician at the General Hospital of Athens Laikon. Currently, I am Senior Consultant at the Hellenic NHS and Scientific Associate at the National and Kapodistrian University of Athens.

Curriculum vitae

NAME:	Maria N. Gamaletsou, MD, PhD, MPH
PRESENT TITLE AND AFFILIATION:	Senior Consultant at the Hellenic NHS, General Hospital of Athens Laikon, Athens, Greece Scientific Associate at the National and Kapodistrian University of Athens
CITIZENSHIP	Greek
OFFICE ADDRESS:	Athens University Medical School, Mikras Asias 75 Athens, 115 27
MOBILE PHONE:	+30-2107462667
E-MAIL:	magama@med.uoa.gr

MEDICAL LICENSE

Number #6283/5Aug2003, Prefecture of Eastern Attica, Greece

MEDICAL EDUCATION

Doctor of Medicine (M.D.), 2003

Medical School,
National and Kapodistrian University of Athens, Greece
Grade of certificate: *SUMMA CUM LAUDE* Valedictorian

Doctor of Philosophy (Ph.D.), 2013

Medical School, National and Kapodistrian University of Athens, Greece,
Grade of certificate: *SUMMA CUM LAUDE* Valedictorian

Thesis subject: *Invasive fungal infections in the immunocompromised host*

Master in Public Health (MPH) Degree (2015)

National School of Public Health,
Athens, Greece

POSTDOCTORAL TRAINING

Residency: *Internal Medicine Resident*, Department of Internal Medicine, Laikon General Hospital, Athens, Greece, 4/2007-12/2010 (Director: Professor H.M. Moutsopoulos)

Chief Residency: *Elective*, Weill Cornell Medical Center of Cornell University, New York-Presbyterian Hospital, January – November 2011, (Director: Professor T. J. Walsh)

Fellowship: *Fellow in Infectious Diseases*, Infectious Diseases Unit, Athens University General Hospital “Laikon”, Athens, Greece, June 2012 - June 2014, (Director: Associate Professor N. V. Sipsas)

Observership: *Clinical observer*, HIV department of the Chelsea and Westminster Hospital, London, (2/2014 – 4/2014) (Director: Professor Mark Nelson)

Fellowship: *Senior Clinical Fellow*, National Aspergillosis Center, University Hospital of South Manchester, April 2015 – April 2016 (Director: Professor D. Denning)

Fellowship: *Clinical Fellow in Infectious Diseases*, St James’s University Hospital, The Leeds Teaching Hospitals NHS Trust, January 2017 – March 2018 (Director: Jane Minton)

CURRENT STATUS OF CAREER

Senior Consultant at the Hellenic NHS, Department of Infectious Diseases, University Hospital of Athens Laikon
Scientific Associate at the National and Kapodistrian University of Athens

RESEARCH TRAINING

E-LEARNING RAVE EDC ESSENTIALS FOR INVESTIGATORS WITH DATA ENTRY, MARCH 2013

GCP TRAINING: ICH GOOD CLINICAL PRACTICE E6 (R2) 02/SEPT/2022

RESEARCH EXPERIENCE

I have participated in several clinical trials as Investigator.

1. Research Physician for the study 'Nutritional risk as predictor for healthcare-associated infection among hospitalized elderly patients in the acute care setting and prediction of malnutrition in the elderly' at the Athens Laikon General University, Hospital, Greece; I was involved in the design of protocol, recruitment of patients, analysis and presentation of data.

2. Research Fellow at the Cornell University Medical Centre, NY, USA; I was the Co-founding Member of the International Osteoarticular Mycoses Study Consortium.
3. Research ID Fellow for the study ‘Community-Acquired Bacteraemia (CAB) in Senior Adults: Risk Factors, Outcomes and Correlation with Frailty’ at the LEEDS TEACHING HOSPITALS NHS TRUST, Leeds, UK; I was involved in the design and writing of the protocol.
4. C. DEFINE (ASTELLAS): Epidemiological study on the point prevalence of *C. difficile* in the Greek Hospitals. Research Physician for the CDEFINE study, Athens Laikon General University Hospital, Greece; I was involved in recruitment and follow-ups of patients.
5. FREEDOM STUDY (ASTELLAS): A randomised, controlled, double-blind, parallel group study to compare the efficacy of fidaxomicin to vancomycin in the sustained clinical cure of *Clostridium difficile* Infection in immunocompromised adults. Athens, Greece; I was involved in recruitment and follow-ups of patients.
6. EXTEND STUDY (ASTELLAS): A phase IIIb/IV randomized, controlled, open-label, parallel group study to compare the efficacy of Vancomycin therapy to extended duration Fidaxomicin therapy in the sustained clinical cure of *Clostridium difficile* infection in an older population. Research Physician for the EXTEND study, Athens Laikon General University Hospital, Greece; I was involved in recruitment and follow-ups of patients.
7. FLU IVIG STUDY (INSIGHT – University of Minnesota): ‘Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT 006: FLU-IVIG)’. The purpose of this randomized, double-blind, placebo-controlled trial of Intravenous hyperimmune immunoglobulin (IVIG) in individuals with *influenza* A or B was to determine whether, when added to standard of care (SOC) treatment, administration of IVIG was superior to placebo in terms of reducing disease severity and duration. Leeds, UK (TOP RECRUITERS IN UK).
8. POSY-TEICO study (SANOFI): ‘Prospective, observational cohort, evaluating the incidence of nephrotoxicity, and other adverse events of interest, in patients treated with the higher recommended teicoplanin loading dose (12mg/kg bid), and comparison with external historical comparator data’. This was a non-interventional, prospective cohort, observational Post Authorisation Safety Study (PASS) to evaluate the incidence of nephrotoxicity and safety of patients who were being treated with the higher dose of teicoplanin. The purpose of this study was to collect information about the incidence of nephrotoxicity and other adverse events in patients who were administered a high loading dose of teicoplanin in routine clinical practice. Leeds, UK (TOP RECRUITERS IN UK).
9. Ri-CoDiFy 1 study (Summit Therapeutics): A Phase 3, Randomized, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Ridinilazole (200 mg, Bid) for 10 Days With Vancomycin (125 mg, Qid) for 10 Days in the Treatment of *Clostridium Difficile* Infection (CDI); I am involved in recruitment and follow-ups of patients.
10. CD101.IV.3.05 (EudraCT: 2018-002630-21): ReSTORE Study (Cidara Therapeutics Inc.): A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection vs. Intravenous Caspofungin Followed by Oral Fluconazole Step Down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis; I am involved in recruitment and follow-ups of patients.

11. AIC316-03-II-01 (EudraCT: 2020-004940-27): Μία τυχαιοποιημένη, ανοικτής επισημάνσης, πολυκεντρική, συγκριτική δοκιμή για την αξιολόγηση της αποτελεσματικότητας και της ασφάλειας του pritelivir έναντι της φοσκαρνέτης για την θεραπεία των ανθεκτικών στην ακυκλοβίρη βλεννογονοδερματικών λοιμώξεων από HSV σε ανοσοκατεσταλμένους ασθενείς (PRIOH-1)
12. Effects of an Antimicrobial Stewardship (AMS) Program, on the prevalence of multidrug-resistant Gram-negative pathogens, in an area of high consumption of antibiotics and high resistance rates
13. INSIGHT 011/ FLU 003 (ICOS): Μια διεθνής μελέτη παρατήρησης για την περιγραφή ενηλίκων που νοσηλεύονται με γρίπη ή άλλους επιλεγμένους αναπνευστικούς ιούς/στόχους-Μελέτη αναπνευστικών ιών σε νοσηλευόμενους ασθενείς
14. INSIGHT 012 (OTAC) (EudraCT: 2021-001663-24): Μια Διεθνής Πολυκεντρική, Τυχαιοποιημένη, Διπλά-Τυφλή, Ελεγχόμενη με Εικονικό Φάρμακο Δοκιμή Ασφάλειας και Αποτελεσματικότητας της Έναντι Κορονοϊού Υπεράνοσης Ενδοφλέβιας Ανοσοσφαιρίνης για τη Θεραπεία Ενηλίκων Περιπατητικών Ασθενών σε Πρώιμα Στάδια της COVID-19

RESEARCH INTERESTS

Invasive Fungal Infections (IFIs) in Immunocompromised Host; *Aspergillus* and Pulmonary Diseases; HIV Infection; Nosocomial Infections; Osteoarticular Infections; Antimicrobial and Antifungal Stewardship; Hospital Infection Control.

INVITED SPEAKER IN NATIONAL AND INTERNATIONAL CONFERENCES:


Invited speaker in more than 10 International and National Conferences.

REVIEWER IN «PEER-REVIEWED» JOURNALS: in more than 20 in a period of 10 years.

BIBLIOGRAPHY: 50 published papers in peer-reviewed journals in a period of 14 years.

Signature:

Date: 7Dec2022



Παραθέσεις	2189	1592
h-index	22	20
i10-index	31	29

